Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

The panel voted 21 to zero that Beyfortus (nirsevimab) appears to be safe and effective at preventing RSV infections in newborns and infants as they face their first RSV season, setting the drug ...

a new golden child could be emerging in the form of Beyfortus. During its first full year on the market, the respiratory syncytial virus (RSV) antibody easily broke the $1 billion sales threshold.

One Zelienople child survived a serious health scare after coming down with respiratory syncytial virus in late January. The ...

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good ...

Dr. Patrick Hemmons travelled to Seattle to get an RSV shot for his daughter. He says he hopes to see nirsevimab become more easily accessible across the country.

Therapeutics Market Growth is Driven by Increased Awareness of RSV’s Health Risks and The Development of Advanced Treatment Options.Pune, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Respiratory Syncytial Virus ...

Get Your Free Sample Market Report: What is behind the incessant drive of the beyfortus global market ? The increasing incidence of RSV cases continues to propel the market ahead. RSV is an ...

A nationwide surge in flu, COVID-19, RSV and norovirus infections is fueling concerns of a possible virus "quademic." Or is it just winter? The three respiratory viruses plus norovirus ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t afford to pay $350 for a one-off vaccine.